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Most vaccines used for humans work through humoral immunity, yet many appear to be
protective even after specific circulating antibody levels have waned to undetectable levels.
Furthermore, it has been difficult to define a serologic correlate of protection against a number
of infectious diseases, including those caused by Bordetella pertussis. B. pertussis clearance in
immunized mice has been shown to correlate with pertussis vaccine efficacy in children. This
murine respiratory challenge model was used to demonstrate persistent vaccine-induced pro-
tection against B. pertussis in the absence of circulating antibody at the time of challenge.
Whole-cell and acellular pertussis vaccines induced persistent memory T and B cells and
anamnestic antibody responses after challenge. The findings suggest that immunologic mem-
ory is more significant in protection than is the induction of immediate antibody responses
and imply that vaccinated children still may be protected against disease following the dis-
appearance of specific serum IgG.
Whole-cell pertussis vaccines appear to induce long-lasting
immunity against severe whooping cough in children and young
adults. However, concern about the safety of whole-cell vac-
cines has resulted in the development of acellular pertussis vac-
cines prepared from purified components of Bordetella pertussis.
The new vaccines, which have a higher safety profile, have
replaced whole-cell vaccines in many developed countries. Re-
sults from clinical trials have indicated that acellular pertussis
vaccines confer relatively high levels of protection against severe
disease [1–4], but these studies have not provided definitive
information about a relationship between antibody levels
against protective antigens and immune protection. Follow-up
studies have indicated that antibody responses in immunized
children decline to low or undetectable levels 2 years after a
complete course of vaccination [5, 6]. These children do not
appear to be developing overt disease [7], but, without a history
of exposure and the application of sensitive indicators of in-
fection in large postimmunization surveillance programs, it is
impossible to determine whether they are immune to infection
and to establish the mechanisms that mediate protection. Al-
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though these fundamental questions are difficult to answer in
a clinical setting, we have been able to address them by use of
a well-established animal model.
By use of a murine respiratory challenge model of B. pertussis
infection, in which protection correlates with vaccine efficacy
in human clinical trials, together with gene knockout mice, we
have identified complementary roles for cellular and humoral
immunity in protection [8–11]. In our study, we used this model
to examine the relationship between the persistence of the im-
mune response and the development of immunologic memory
and protection against respiratory infection.
Materials and Methods
Immunization. BALB/c mice were immunized intraperitoneally
(at 0 and 4 weeks) with 0.04 human dose of either Wellcome whole-
cell pertussis vaccine (British Reference reagent 88/522; National
Institute for Biological Standards and Control, Potters Bar, Herts-
fordshire, UK) or Chiron acellular pertussis vaccine (Chiron Vac-
cines, Siena, Italy), equivalent to 0.2 mg of recombinant pertussis
toxin (PT), 0.1 mg of filamentous hemagglutinin (FHA), and 0.1
mg of pertactin (PRN). Control mice were immunized with adjuvant
(alum) only.
Challenge and course of B. pertussis infection. Respiratory in-
fection of mice with B. pertussis was initiated by aerosol challenge
as described elsewhere [8]. The kinetics of bacterial clearance were
determined by counting colony-forming units (cfu) in the lungs on
days 0, 3, 7, 14, and 21 after challenge [8]. Results are reported as
the mean number of viable B. pertussis for individual lungs from
at least 4 mice per time point per experimental group.
Antibody responses. The levels of serum antibody to B. per-
tussis and bacterial components were determined by ELISA as
described elsewhere [9]. B. pertussis sonicate (5.0 mg/mL) or PT,
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PRN, or FHA (1.0 mg/mL of each) were used to coat plates. Bound
antibodies were detected by use of alkaline phosphatase–conju-
gated anti–mouse IgG. Antibody levels are expressed as the mean
end-point titer (5SE), determined by extrapolation of the straight
part of the titration curve to 2 SE above the background value
(OD <0.2) obtained with nonimmune mouse serum. Assays were
standardized with reference antiserum prepared from mice im-
munized with the British reference preparation of whole-cell per-
tussis vaccines [9]. Titers >1/20 (1.3 log10) were considered positive.
T cell cytokine assays. Spleen cells from individual mice were
tested at different time points after immunization and after chal-
lenge for in vitro cytokine production in response to heat-killed B.
pertussis (106/mL), PT (5.0 mg/mL; heat-inactivated at 807C for 20
min), FHA (5.0 mg/mL), PRN (5.0 mg/mL), concanavalin A (2 mg/
mL), or medium alone as control. Supernatants were removed from
triplicate cultures after 72 h, and interferon-g and interleukin-4
concentrations were determined by immunoassay [7].
Assessment of memory B cells. Antibody-forming cells were
quantified by an insoluble substrate B. pertussis–specific ELISPOT.
The wells of plates (Multiscreen HA; Millipore, Bedford, MA) were
coated overnight with 100 mL of sonicated B. pertussis or inacti-
vated PT (5 mg/mL). Both surfaces of the membrane were washed
5 times aseptically with PBS and then were blocked for 1 h with
8% (vol/vol) fetal calf serum in RPMI medium. After blocking,
spleen or peripheral blood mononuclear cell preparations were
added to quadruplicate wells at concentrations from to41 3 10
/mL and were incubated at 377C with 5% CO2 for 2 days.
71 3 10
After being washed 6 times in PBS, plates were incubated for 2 h
with horseradish peroxidase–conjugated goat anti–mouse IgG
(Sigma, Dorset, UK). Plates were washed 3 times more before the
addition of 200 mL/well 3-amino-9-ethylcarbazole substrate buffer.
After 45 min, this was removed, and the plates were washed once
with water and allowed to air dry. Spots representing individual
antibody-forming cells were counted by use of a zoom stereo
microscope.
Results
Acellular and whole-cell pertussis vaccines protect against B.
pertussis after the disappearance of serum IgG responses. Im-
munization of mice with 2 low doses of either a whole-cell or
an acellular pertussis vaccine induced strong serum IgG re-
sponses against PT, FHA, and PRN, but antibody levels de-
clined rapidly after 3 months and were undetectable by 6–9
months (figure 1A). Immunized mice were challenged with B.
pertussis either at the peak of the antibody response 6 weeks
after primary immunization or once circulating antibody titers
had waned, 44 weeks after primary immunization. Despite the
decline in B. pertussis–specific serum IgG to undetectable levels,
both vaccines still conferred protection against B. pertussis
when challenged 44 weeks after immunization (figure 1B). The
numbers of bacteria in the lungs were significantly higher in
control than in either whole-cell vaccine– or acellular vaccine–
immunized mice at all time points tested ( ). In par-P ! .01–.001
ticular, mice immunized with whole-cell pertussis vaccines dis-
played a high level of protection that was equivalent to that
observed at the peak of the antibody response 6 weeks after
immunization; counts of cfu were significantly greater in whole-
cell vaccine– than in acellular vaccine–immunized mice 3, 7,
and 10 days after challenge at 44 weeks.
Immunization induces memory T and B cells. Recall T cell
responses to B. pertussis antigens persisted in whole-cell vac-
cine– and acellular vaccine–immunized mice, and, on the day
of challenge at 44 weeks after primary immunization, B. per-
tussis–specific T cell responses clearly were detectable in im-
munized mice (figure 2A). Whole-cell pertussis vaccine induced
a Th1-dominated response, whereas acellular pertussis vaccine
induced a Th2-type response, and these patterns of cytokine
secretion persisted for at least 44 weeks. However, 14 days after
challenge, the cytokine profile of B. pertussis antigen–stimulated
spleen cells from mice immunized with acellular pertussis vac-
cine had switched to a mixed Th1/Th2-type response (18–33
ng/mL interferon-g and 100–217 pg/mL interleukin-4), whereas
the Th1 response was maintained in mice immunized with
whole-cell pertussis vaccine (58–160 ng/mL interferon-g and
undetectable interleukin-4).
Memory B cells specific for B. pertussis also were induced
by immunization with whole-cell and acellular pertussis vac-
cines and persisted for at least 44 weeks after vaccination. By
use of an ELISPOT technique, specific antibody-forming cells
were detected in peripheral blood mononuclear cells and spleen
cells after stimulation with PT or B. pertussis sonicate (figure
2B). Significantly greater numbers of B. pertussis–specific B cells
could be detected in the blood and spleens of immunized mice
than in those of controls. Memory induction was confirmed by
the observation of an anamnestic antibody response to B. per-
tussis antigens in immunized mice after challenge (figure 1A).
IgG responses to B. pertussis could not be detected in unim-
munized control mice for at least 21 days after challenge. In
contrast, 7 days after challenge, circulating antibodies were de-
tected against PRN and B. pertussis sonicate in whole-cell vac-
cine–immunized mice and against PRN and PT in acellular
vaccine–immunized mice.
Discussion
Our study demonstrates that circulating antibody, considered
to be the major effector mechanism against viruses and bacteria,
need not be detectable at the time of exposure for the main-
tenance of vaccine-induced protective immunity against a bac-
terial pathogen of humans. Protective levels of circulating an-
tibody have been identified for certain pathogens, such as
poliovirus, the agents of diphtheria and tetanus, and Haemo-
philus influenzae. However, certain persons who have antibody
levels below these threshold values appear to be protected. Fur-
thermore, it has been difficult to establish protective levels of
antibody induced with certain vaccines, including those against
pertussis [1–4]. Recent reports from household contact studies
have indicated that antibody responses to PT, PRN, and fim-
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Figure 1. Persistence of protection against Bordetella pertussis respiratory infection after decline in specific serum IgG to undetectable levels.
Mice were immunized at weeks 0 and 4 with 0.04 human dose of whole-cell pertussis vaccine (Pw) or acellular pertussis vaccine (Pa) or with
adjuvant only as control. A, Serum antibody responses to B. pertussis (BP) sonicate, pertussis toxin (PT), filamentous hemagglutinin (FHA), and
pertactin (PRN), detected by ELISA at intervals after immunization and 1, 2, and 3 weeks after respiratory challenge. B, Immunized and control
mice after exposure to aerosol challenge with B. pertussis 6 or 44 weeks after primary immunization. Results are mean (5SE) colony-forming
units (cfu) in lungs, estimated for 4 mice/group at each time point (error bars are smaller than symbols at certain time points for control mice).
* ; ** , whole-cell vs. acellular vaccine (Mann-Whitney U test).P ! .05 P ! .01
briae may correlate with absence of severe disease [7, 12]. Al-
though these studies suggested that antibodies to PRN and
fimbriae are the most important, a monocomponent pertussis
toxoid vaccine conferred 71% protection against severe disease
in a clinical trial [4]. Furthermore, antibody levels in children
decline rapidly after vaccination [5, 6, 13]. The results of the
present study suggest that, if exposed to B. pertussis, these chil-
dren still would be protected against developing whooping
cough.
There are a number of explanations for the maintenance of
protection after the decline in circulating anti–B. pertussis an-
tibody. It is possible that antibody does not play a role in
protection and that immunity is conferred exclusively by cel-
lular mechanisms. Analysis of cell-mediated immunity in mice
demonstrated that specific T cell responses were maintained up
to the time of challenge, 44 weeks after immunization. Whole-
cell pertussis vaccines selectively induced B. pertussis–specific
Th1 cells, whereas acellular pertussis vaccines induced T cells
more polarized to the Th2 subtype, which is consistent with
reports on short-term immunization [8, 9]. We have suggested
elsewhere that the Th1 subpopulation confers optimal protec-
tion against B. pertussis [8–11] and that these cells may function
by promoting the antibacterial activity of macrophages and
neutrophils and by stimulating opsonizing antibodies. However,
acellular pertussis vaccines also can confer a high level of pro-
tection against severe disease, and this appears to be mediated
solely by antibody with help from Th2 cells. The slightly lower
levels of bacteria in the lungs of whole-cell vaccine–immunized
mice, compared with acellular vaccine–immunized mice after
challenge at 44 weeks, is consistent with previous studies on
short-term protection with a range of whole-cell and acellular
pertussis vaccines [8] and may reflect the contribution of cell-
mediated immunity to protection. Nevertheless, the results sug-
gest that the Th1/Th2 dichotomy does not impinge on memory
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Figure 2. Recall T and B cell responses to Bordetella pertussis antigens after immunization with whole-cell pertussis vaccine (Pw) or acellular
pertussis vaccine (Pa). A, 44 Weeks after immunization, spleen cells ( /mL) were incubated with heat-inactivated pertussis toxin (PT),62 3 10
filamentous hemagglutinin (FHA), pertactin (PRN), heat-killed B. pertussis (BP), concanavalin A (Con A) or medium only as positive and negative
controls, respectively. Supernatants were removed after 72 h and assessed for interferon-g (IFN-g) and interleukin-4 (IL-4). Results are mean
(5SE) cytokine concentrations for 4 mice/group, assayed in triplicate. Cytokines were undetectable in supernatants from cells stimulated with
medium alone. B, 44 Weeks after immunization, peripheral blood mononuclear cells and spleen cells from immunized or control mice were
incubated in plates coated with B. pertussis sonicate (BP) or inactivated PT, and nos. of specific antibody-forming cells (AFC) were determined
by ELISPOT. Results are mean values (5SE) for triplicate determinations from 4–6 mice/group. Cytokine and AFC data are representative of
4 different time points after immunization in 2 independent experiments, with similar levels of statistical significance at each determination.
* ; ** ; *** vs. control (Student’s t test).P ! .05 P ! .01 P ! .001
induction. Furthermore, although these patterns of cytokine
secretion are stable, they are not immutable or “locked in.”
After bacterial challenge, there is a broadening of the pattern
of cytokine responses observed in acellular pertussis vaccine–
immunized mice, from a Th2 response 7 days after challenge
to a mixed Th1/Th2 or Th0-type response thereafter. In a study
of children immunized with acellular pertussis vaccines, the
mixed Th1/Th2 profile observed early after vaccination [14, 15]
had switched to a Th1-type response 3–4 years later [13]. It was
suggested that exposure to subclinical infections, which would
enhance Th1 responses, may explain the persistent protection
against typical pertussis, despite a substantial waning of both
antibody and T cell responses induced by the primary immu-
nization [13].
An alternative, but not mutually exclusive, hypothesis to ex-
plain long-term protection in children after declining antibody
responses is that immune effector mechanisms generated from
memory B and T cells after bacterial exposure are capable of
clearing the bacteria from the respiratory tract. This is consis-
tent with our study and with recent suggestions that antibodies
against multiple antigens can mediate protection against B. per-
tussis [3, 8]. Given the long incubation period of B. pertussis
infection, anamnestic antibody responses after exposure may
be sufficient to protect against severe whooping cough. How-
ever, it appears that current pertussis vaccines do not confer
sterilizing immunity against B. pertussis. These vaccines are
capable of preventing severe disease but are less efficient when
judged on the criterion of preventing infection or mild disease,
even in the presence of high levels of circulating antibody at
the time of infection. Although the induction of a given con-
centration of circulating antibody early after vaccination may
still provide a useful correlate of protection, in that it may
predict the level of B cell priming, it is not clear that it will
predict the extent of memory T and B cell induction. Although
we do not yet have definitive information on the relative im-
portance of T or B cell memory, we have demonstrated else-
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where that short-term memory B and T cells both contribute
to protection induced by natural infection [10].
Our findings have important implications for pertussis vac-
cination policy in relation to the level of protection in the face
of waning antibody levels and the need for booster immuni-
zation. The data from the mouse model suggest that persistence
of circulating antibody is not a prerequisite for the maintenance
of protective immunity. These observations also have impli-
cations for the evaluation and development of vaccines against
a range of infectious diseases. Although circulating neutralizing
antibodies clearly are important to confer sterilizing immunity,
especially against viral infections, it also appears that certain
vaccines can protect by recall of immunologic memory at the
T and B cell level.
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